Co-trimoxazole, cART, and non-AIDS infectious diseases

The Lancet

Volumn 375, Issue 9722, 2010, Pages 1231-1233

  Anglaret, Xavier ^a   Eholie, Serge ^b  

^a INSERM   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; COTRIMOXAZOLE;

AFRICA; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE SEVERITY; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; INDUSTRIALIZATION; INFECTION PREVENTION; MORTALITY; PNEUMOCYSTOSIS; PRIORITY JOURNAL; TOXOPLASMOSIS;

EID: 77950628521     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60200-0     Document Type: Note

References (13)

1. Walker A.S., Ford D., Gilks C.F., et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet (2010) 10.1016/S0140-6736(10)60057-8 published online March 29.
2. Weverling G.J., Mocroft A., Ledergerber B., et al., for the EuroSIDA Study Group. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet 353 (1999) 1293-1298
3. Anglaret X., Chêne G., Attia A., et al., the Cotrimo-CI study group. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 353 (1999) 1463-1468
4. Wiktor S.Z., Sassan-Morokro M., Grant A.D., et al. Efficacy of trimethropim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Lancet 353 (1999) 1469-1475
5. Mermin J., Lule J., Ekwaru J.P., et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 364 (2004) 1428-1434
6. Corbett E.L., Churchyard G.J., Charalambos S., et al. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 34 (2002) 1251-1258
7. Gilks C.F., Ojoo S.A., Ojoo J.C., et al. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet 347 (1996) 718-723
8. Hirschtick R.E., Glassroth J., Jordan M.C., et al., for the Pulmonary Complications of HIV Infection Study Group. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med 333 (1995) 845-851
9. Whitworth J., Morgan D., Quigley M., et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 356 (2000) 1051-1056
10. Anglaret X., Messou E., Ouassa T., et al., for the ANRS 1203 Study Group. Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Cote d'Ivoire. AIDS 17 (2003) 575-584
11. WHO. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: recommendations for a public health approach. http://www.who.int/hiv/pub/plhiv/ctx/en (accessed Feb 15, 2010).
12. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375 (2010) 123-131
13. Losina E., Yazdanpanah Y., Deuffic-Burban S., et al. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Cote d'Ivoire. Antivir Ther 12 (2007) 543-551